MarketInOut Stock Screener Log In | Sign Up
 

Cullinan Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
Cullinan Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization858.57 mln
Float48.50 mln
Earnings Date11/05/2026

Piotroski F-Score

1 / 9
Very weak

1-Year Forecast

34.50
Transformational upside

Relative Strength

35 / 100
Underperforming

Debt / Equity

0.01
Debt-free

ROE

-50.16
Deeply negative

ROA

-46.09
Deeply negative

Business Description

Cullinan Therapeutics is a Cambridge, Massachusetts-based drug development company focused on finding new treatments for cancer and autoimmune conditions. The company is currently running multiple clinical trials, testing several experimental medicines including targeted therapies for blood cancers, lung cancer, and autoimmune diseases. Cullinan works alongside a number of partners, including Taiho Pharmaceutical and Chongqing Genrix Biopharmaceutical, to bring its treatments to patients. Founded in 2016, the company operates under its current name following a rebranding in 2024.

Key Fundamentals

EPS-3.11
ROE-50.16
ROIC-191
ROA-46.09
EBITDA, mln-204
EV / EBITDA-3.02
EV / EBIT-3.02

Quote Details

Last 14.37
Change -0.55 (-3.69%)
Open 14.95
Volume 485,201
Turnover 6,972,338
Average Volume 947,061

Financial Ratios

Leverage Ratio1.13
Current Ratio8.42
Price / Book3.09
Price / Tangible Book3.09
Debt / Equity0.01

Financial Strength

Piotroski F-Score 1 / 9
1-Year Target Price34.50
Short Ratio6.32
Short % of Float16.52

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 11.14% 93 / 100   
1 Month -6.93% 45 / 100   
2 Months -17.89% 29 / 100   
6 Months 8.7% 70 / 100   
1 Year 76.97% 89 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog